HomeCompareBICTF vs JEPI

BICTF vs JEPI: Dividend Comparison 2026

BICTF yields 20000.00% · JEPI yields 8.56%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BICTF wins by $52481917574412746752.00M in total portfolio value
10 years
BICTF
BICTF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full BICTF calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.56%
Share price
$55.65
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$1,573.67
Full JEPI calculator →

Portfolio growth — BICTF vs JEPI

📍 BICTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBICTFJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BICTF + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BICTF pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BICTF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
JEPI
Annual income on $10K today (after 15% tax)
$727.38/yr
After 10yr DRIP, annual income (after tax)
$1,337.62/yr
At 15% tax rate, BICTF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BICTF + JEPI for your $10,000?

BICTF: 50%JEPI: 50%
100% JEPI50/50100% BICTF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BICTF buys
0
JEPI buys
0
No recent congressional trades found for BICTF or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBICTFJEPI
Forward yield20000.00%8.56%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52481917574412746752.00M$29.3K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$1,573.67
Total dividends collected$52448189483771600896.00M$12.0K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: BICTF vs JEPI ($10,000, DRIP)

YearBICTF PortfolioBICTF Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,276$855.74+$2.00MBICTF
2$377,983,225$375,831,775.70$12,675$926.02+$377.97MBICTF
3$66,433,479,469$66,029,037,418.28$14,207$999.01+$66433.47MBICTF
4$10,916,985,471,987$10,845,901,648,955.73$15,878$1,074.57+$10916985.46MBICTF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$17,697$1,152.57+$1677384363.75MBICTF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$19,674$1,232.87+$240985175079.12MBICTF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$21,815$1,315.29+$32373573631143.68MBICTF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$24,131$1,399.68+$4066766648320630.00MBICTF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$26,630$1,485.86+$477730483406513344.00MBICTF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$29,323$1,573.67+$52481917574412746752.00MBICTF

BICTF vs JEPI: Complete Analysis 2026

BICTFStock

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Full BICTF Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this BICTF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BICTF vs SCHDBICTF vs OBICTF vs KOBICTF vs MAINBICTF vs JEPQBICTF vs XYLDBICTF vs DIVOBICTF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.